Summary
DexCom, Inc. reported increased product revenue of $72.8 million for the first quarter of 2015, a significant rise from $46.7 million in the same period of 2014, driven by strong sales volume of its G4 PLATINUM continuous glucose monitoring system. Despite this revenue growth, the company continued to incur net losses, reporting a net loss of $12.9 million for the quarter, compared to $12.5 million in the prior year. Operating expenses, particularly in research and development and selling, general, and administrative functions, saw increases, reflecting investments in future product development and commercialization efforts. The company's liquidity position remains adequate, with $83.8 million in cash, cash equivalents, and marketable securities as of March 31, 2015, and management believes these resources are sufficient to fund operations through at least March 31, 2016. Key strategic developments include the commercialization of the DexCom G4 PLATINUM with Share remote monitoring system in early 2015, which allows for remote monitoring of glucose information by designated recipients. The company also noted progress in its manufacturing operations and an ongoing focus on expanding its direct sales force and distribution networks. While the company is experiencing substantial revenue growth, the persistent net losses and significant accumulated deficit highlight the ongoing investment phase of its business. Investors should monitor the company's ability to achieve profitability, manage operating expenses, and secure necessary regulatory approvals for future products.
Financial Highlights
43 data points| Revenue | $72.80M |
| Cost of Revenue | $26.30M |
| Gross Profit | $46.50M |
| R&D Expenses | $19.80M |
| SG&A Expenses | $39.40M |
| Operating Expenses | $59.20M |
| Operating Income | -$12.70M |
| Interest Expense | $200K |
| Net Income | -$12.90M |
| Shares Outstanding (Basic) | 311.20M |
Key Highlights
- 1Product revenue increased by 56% to $72.8 million in Q1 2015 compared to $46.7 million in Q1 2014, primarily driven by higher sales volume of the G4 PLATINUM system.
- 2Net loss for the quarter was $12.9 million, a slight increase from $12.5 million in the prior year's quarter.
- 3Operating expenses increased, with R&D up 37% to $19.8 million and SG&A up 43% to $39.4 million, reflecting investments in future growth.
- 4The company commercialized the G4 PLATINUM with Share remote monitoring system in Q1 2015, enhancing patient connectivity and data sharing capabilities.
- 5Total cash, cash equivalents, and marketable securities stood at $83.8 million as of March 31, 2015, providing sufficient liquidity for operations through at least March 31, 2016.
- 6Share-based compensation expense significantly increased to $15.9 million in Q1 2015 from $8.7 million in Q1 2014, impacting operating expenses.
- 7The company continues to expand its global reach through direct sales and distribution arrangements, with revenue from Stocking Distributors increasing to 61% of total revenue.